TMO

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2006, for Thermo Fisher Scientific Inc. The reporting period is defined by the completion of the company's merger with Fisher Scientific International Inc. on November 9, 2006. Following the merger, the company operates as the world leader in serving science, organized into two primary segments: Analytical Technologies and Laboratory Products and Services. The company serves over 350,000 customers globally with approximately 30,500 employees.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 44% to $3.79 billion. Approximately 32% of this growth was attributable to the Fisher merger, with the remaining growth driven by a 6% increase in organic sales due to higher demand and price increases.
• Profitability Decline: Operating income decreased 8% to $242 million, and the operating margin contracted from 10.0% to 6.4%. This decline was primarily due to $125 million in pre-tax charges associated with the Fisher merger (including inventory revaluation and accelerated equity compensation) and $93 million in higher amortization expense related to acquired intangible assets.
• Balance Sheet Expansion: Total assets surged from $4.25 billion to $21.26 billion, and long-term obligations increased from $469 million to $2.18 billion, reflecting the assumption of Fisher's debt and the recording of goodwill ($8.5 billion) and intangible assets ($7.5 billion) from the merger.
• Backlog: Firm order backlog increased significantly to $1.08 billion from $528 million, driven principally by the inclusion of Fisher's backlog.

Guidance, Outlook, and Risks

• Merger Integration: Management is focused on integrating Fisher's operations to realize cost savings and synergies. The company expects to finalize restructuring plans for Fisher within one year of the merger date. Future benefits from productivity initiatives are expected to be smaller than in previous years.
• Capital Expenditures: The company expects capital expenditures for 2007 to approximate $240 million to $260 million.
• Debt Covenants: The company is subject to a financial covenant requiring a Consolidated Leverage Ratio (Indebtedness to EBITDA) not to exceed 3.0 to 1.0. Failure to comply could trigger an event of default.
• Key Risks:
  • Integration Risk: Failure to successfully combine the businesses of Thermo and Fisher could prevent the realization of anticipated cost savings and operating synergies.
  • Goodwill Impairment: With $8.5 billion in goodwill, the company faces the risk of material impairment charges if future cash flows decline or if the integration is unsuccessful.
  • Intellectual Property Litigation: The company is involved in patent infringement litigation regarding mass spectrometer systems (Applied Biosystems/MDS Scientific Instruments), where an unfavorable outcome could have a material adverse effect.
  • Regulatory and Environmental: The company faces ongoing environmental remediation obligations, with accrued liabilities of approximately $24 million, and is subject to complex regulations regarding product safety and environmental compliance.

Investor Verification Checklist

• Merger Synergies: Verify the progress of cost-saving initiatives and the timeline for realizing the anticipated benefits of the Fisher merger.
• Amortization Impact: Monitor the impact of the ~$470 million annual amortization expense associated with Fisher's intangible assets on future operating margins.
• Debt Servicing: Assess the company's ability to service its increased debt load ($2.7 billion) and maintain compliance with the 3.0x leverage covenant.
• Legal Contingencies: Track the status of the patent infringement lawsuit regarding mass spectrometers and potential environmental remediation costs.
• Goodwill Valuation: Review future annual impairment tests for the $8.5 billion goodwill balance, particularly in light of integration challenges.